Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-04-26 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券申请文件的审核问询函的回复（2021年财务数据更新）
Audit Report / Information Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shanghai Stock Exchange regarding Shenzhen Microchip Biotechnology Co., Ltd.'s application for issuing convertible bonds to unspecified objects. It includes extensive discussion on the use of raised funds, project descriptions, investment plans, product development stages, market analysis, and risk assessments. The document references a '募集说明书' (prospectus) and includes detailed financial and operational information related to the bond issuance and the company's projects. The presence of a regulatory inquiry response, detailed project and financial explanations, and the context of bond issuance application indicate this is an Audit Report / Information type document, specifically a regulatory inquiry response related to a financing activity but not a simple announcement or presentation. It is not an Annual Report, Earnings Release, or a simple announcement. It contains substantive financial and operational data and explanations. Therefore, the best fitting category is Audit Report / Information (AR). FY 2021
2022-04-26 Chinese
关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券审核中心意见落实函的回复（2021年财务数据更新）
Capital/Financing Update Classification · 95% confidence The document is a detailed response letter from Shenzhen Microchip Biotechnology Co., Ltd. addressing the Shanghai Stock Exchange's review comments regarding the company's issuance of convertible bonds to unspecified investors. It includes explanations about environmental impact approvals, project progress, and the company's and sponsor's confirmations and statements. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a regulatory response to a review letter related to a financing activity (issuance of convertible bonds). This fits best under Capital/Financing Update (CAP) as it relates to the company's capital raising process and regulatory compliance for the bond issuance.
2022-04-26 Chinese
上海市通力律师事务所关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding Shenzhen Microchip Biotechnology Co., Ltd.'s issuance of convertible corporate bonds to unspecified investors. It includes extensive legal analysis, references to relevant laws and regulations, details about the bond issuance terms, approval and authorization processes, and other legal considerations related to the convertible bond issuance. The document is not a financial report, earnings release, or management discussion, nor is it a simple announcement or certification. It is a specialized legal opinion related to a capital raising activity involving convertible bonds. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP).
2022-04-26 Chinese
简式权益变动报告书(四川能投，更新)
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书（更新）" which translates to a "Simplified Equity Change Report (Update)". It details the change in shareholding of the company 深圳微芯生物科技股份有限公司 (Shenzhen Microchip Biotechnology Co., Ltd.) due to a transfer of equity involving 四川省能源投资集团有限责任公司 and 四川省政府国有资产监督管理委员会. The document extensively discusses the nature of the equity change, the parties involved, the legal and regulatory approvals, and the shareholding percentages before and after the change. It also references relevant securities laws and disclosure obligations. There is no indication that this is an annual report, earnings release, or any other financial report. Instead, it is a formal notification of a significant change in shareholding stakes, consistent with a Major Shareholding Notification filing. The document length and detail confirm it is the report itself, not just an announcement of a report publication. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2022-04-25 Chinese
简式权益变动报告书（清华大学，更新）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书（更新）" which translates to "Simplified Equity Change Report (Update)". It details the change in shareholding by Tsinghua University in Shenzhen Microchip Biotechnology Co., Ltd., including the reduction of shares held due to a transfer of equity. The document includes sections on the purpose of the equity change, the method of change, approvals, and other related disclosures. It is a formal report on a change in shareholding, consistent with notifications of major shareholding changes. There is no indication that this is an annual report, earnings release, or other financial report. The document is not a mere announcement of a report but a detailed disclosure of shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2022-04-25 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2021 Annual General Meeting (AGM) resolutions of Shenzhen Microchip Biotechnology Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2021 annual report, financial statements, profit distribution, and other corporate matters. The document includes voting results and legal witness statements confirming the validity of the meeting and resolutions. The content is focused on the official announcement of the voting results from the AGM rather than the full report or detailed financial statements themselves. The document length is relatively short (3811 characters) and it primarily serves as a formal disclosure of the AGM resolutions and voting outcomes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-04-20 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.